Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT GLENMARK PHARMA/
WOCKHARDT
 
P/E (TTM) x 15.5 -45.9 - View Chart
P/BV x 2.1 1.0 211.3% View Chart
Dividend Yield % 0.5 0.0 12,350.6%  

Financials

 GLENMARK PHARMA   WOCKHARDT
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
WOCKHARDT
Mar-18
GLENMARK PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs7121,012 70.3%   
Low Rs484532 91.0%   
Sales per share (Unadj.) Rs349.6355.9 98.2%  
Earnings per share (Unadj.) Rs32.8-60.3 -54.4%  
Cash flow per share (Unadj.) Rs44.3-46.8 -94.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 25,828.3%  
Book value per share (Unadj.) Rs198.6257.8 77.1%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.2 78.8%   
Avg P/E ratio x18.2-12.8 -142.4%  
P/CF ratio (eoy) x13.5-16.5 -81.7%  
Price / Book Value ratio x3.03.0 100.5%  
Dividend payout %6.10 -36,775.5%   
Avg Mkt Cap Rs m168,62585,379 197.5%   
No. of employees `00012.06.3 192.5%   
Total wages/salary Rs m20,5619,371 219.4%   
Avg. sales/employee Rs Th8,196.06,295.0 130.2%   
Avg. wages/employee Rs Th1,708.11,498.3 114.0%   
Avg. net profit/employee Rs Th768.5-1,066.3 -72.1%   
INCOME DATA
Net Sales Rs m98,65539,369 250.6%  
Other income Rs m2,0811,202 173.1%   
Total revenues Rs m100,73640,571 248.3%   
Gross profit Rs m15,85818 86,656.4%  
Depreciation Rs m3,2591,495 218.0%   
Interest Rs m3,3462,555 131.0%   
Profit before tax Rs m11,335-2,830 -400.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-3,582 -46.7%   
Tax Rs m3,756257 1,461.6%   
Profit after tax Rs m9,250-6,669 -138.7%  
Gross profit margin %16.10 34,581.0%  
Effective tax rate %33.1-9.1 -364.9%   
Net profit margin %9.4-16.9 -55.4%  
BALANCE SHEET DATA
Current assets Rs m66,96833,796 198.2%   
Current liabilities Rs m40,21126,917 149.4%   
Net working cap to sales %27.117.5 155.2%  
Current ratio x1.71.3 132.6%  
Inventory Days Days8379 105.0%  
Debtors Days Days8189 91.0%  
Net fixed assets Rs m33,32239,664 84.0%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m55,77027,968 199.4%   
Net worth Rs m56,05228,522 196.5%   
Long term debt Rs m35,73821,731 164.5%   
Total assets Rs m132,88881,620 162.8%  
Interest coverage x4.4-0.1 -4,080.8%   
Debt to equity ratio x0.60.8 83.7%  
Sales to assets ratio x0.70.5 153.9%   
Return on assets %9.5-5.0 -188.1%  
Return on equity %16.5-23.4 -70.6%  
Return on capital %17.8-7.7 -232.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9989,807 642.4%   
Fx outflow Rs m22,8591,789 1,278.0%   
Net fx Rs m40,1408,019 500.6%   
CASH FLOW
From Operations Rs m13,242684 1,934.8%  
From Investments Rs m-6,9906,302 -110.9%  
From Financial Activity Rs m-7,387-7,695 96.0%  
Net Cashflow Rs m-2,971-664 447.4%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  FULFORD INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 10, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SUVEN LIFESCIENCES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS